Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > Octreotide Long-Acting Injection Obtains Clinical Trial Approval

Octreotide Long-Acting Injection Obtains Clinical Trial Approval

January 19, 2023

202307.png

202308.png

Previous: NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA

Next: levidipine Injectable Emulsion Obtains Clinical Approval

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat